Brickell Biotech posts quarterly revenue gain on strength of Botanix deal

BOULDER — Brickell Biotech Inc. (Nasdaq: BBI) reported higher second-quarter revenue, largely on the strength of a recent asset-purchase agreement.

Brickell recorded revenue of $4.3 million, compared with $200,000 in the second quarter of 2021. Most of that — $3 million — came from an upfront payment from Botanix SB, a subsidiary of Botanix Pharmaceuticals Ltd., which acquired all of Brickell’s rights and assets to sofpironium bromide, a potential treatment for primary axillary hyperhidrosis, or excessive underarm sweating. Brickell was on track to submit a New Drug Application to the U.S. Food and Drug Administration for sofpironium bromide gel in mid-2022.

Brickell…